Determined by the subgroup Evaluation, we found that there was significant heterogeneity concerning mortality, favorable results, and the total therapy powerful level. Pertaining to mortality, The explanation for heterogeneity on the subgroup of edaravone dexborneol and EDV was primarily attributed to differences in drug dosage. Concerning favorable results, The rationale https://johnathansqiey.smblogsites.com/33282160/the-2-minute-rule-for-buy-neuroprotectives-online